These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25722446)

  • 1. Feasibility of in situ, high-resolution correlation of tracer uptake with histopathology by quantitative autoradiography of biopsy specimens obtained under 18F-FDG PET/CT guidance.
    Fanchon LM; Dogan S; Moreira AL; Carlin SA; Schmidtlein CR; Yorke E; Apte AP; Burger IA; Durack JC; Erinjeri JP; Maybody M; Schöder H; Siegelbaum RH; Sofocleous CT; Deasy JO; Solomon SB; Humm JL; Kirov AS
    J Nucl Med; 2015 Apr; 56(4):538-44. PubMed ID: 25722446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity
    Kirov AS; Fanchon LM; Seiter D; Czmielewski C; Russell J; Dogan S; Carlin S; Pinker-Domenig K; Yorke E; Schmidtlein CR; Boyko V; Fujisawa S; Manova-Todorova K; Zanzonico P; Dauer L; Deasy JO; Humm JL; Solomon S
    Med Phys; 2018 May; 45(5):2179-2185. PubMed ID: 29480927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL; Chen S; Yeung DW; Cheng TK
    J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique.
    Guo W; Hao B; Chen HJ; Zhao L; Luo ZM; Wu H; Sun L
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):25-32. PubMed ID: 27444682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic PET/CT-guided lung lesion biopsies: impact on diagnostic accuracy and rate of sampling error.
    Guralnik L; Rozenberg R; Frenkel A; Israel O; Keidar Z
    J Nucl Med; 2015 Apr; 56(4):518-22. PubMed ID: 25698780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
    Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
    J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.
    Povoski SP; Hall NC; Murrey DA; Wright CL; Martin EW
    BMC Cancer; 2015 May; 15():378. PubMed ID: 25953144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
    Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
    J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
    Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
    J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation?
    Sainani NI; Shyn PB; Tatli S; Morrison PR; Tuncali K; Silverman SG
    J Vasc Interv Radiol; 2011 Mar; 22(3):354-60. PubMed ID: 21353987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.
    Koopman D; van Dalen JA; Lagerweij MC; Arkies H; de Boer J; Oostdijk AH; Slump CH; Jager PL
    J Nucl Med Technol; 2015 Mar; 43(1):21-7. PubMed ID: 25613334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit?
    Purandare NC; Kulkarni AV; Kulkarni SS; Roy D; Agrawal A; Shah S; Rangarajan V
    Nucl Med Commun; 2013 Mar; 34(3):203-10. PubMed ID: 23353885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose-PET/Computed Tomography-Guided Biopsy.
    Cerci JJ; Tabacchi E; Bogoni M
    PET Clin; 2016 Jan; 11(1):57-64. PubMed ID: 26590444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.